FLT1 and neoplasm: Importantly, the tumor regression observed in B6/129F1 mice upon combined treatment with talazoparib and FLT1 blockade (Figs. 3C–E and EV3I and Figs. 4 and EV4A,B) did not occur in T-cell-deficient nude-Foxn1nu mice (Fig. 6C–E and Fig. 6H–J).